These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39004096)

  • 1. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.
    Eiden J; Fierro C; White A; Davis M; Rhee M; Turner M; Murray B; Herber R; Aitchison R; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    Lancet Infect Dis; 2024 Oct; 24(10):1118-1129. PubMed ID: 39004096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
    Eiden J; Fierro C; Schwartz H; Adams M; Ellis KJ; Aitchison R; Herber R; Hatta Y; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Dec; 227(1):103-112. PubMed ID: 36350017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials.
    Ward BJ; Makarkov A; Séguin A; Pillet S; Trépanier S; Dhaliwall J; Libman MD; Vesikari T; Landry N
    Lancet; 2020 Nov; 396(10261):1491-1503. PubMed ID: 33065035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
    Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of CD8
    Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
    Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V; Cho I; Plested JS; Agrawal S; Fiske J; Cai R; Zhou H; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou B; Lewis M; Price-Abbott P; Patel N; Massare MJ; Smith G; Keech C; Fries L; Glenn GM
    Lancet Infect Dis; 2022 Jan; 22(1):73-84. PubMed ID: 34563277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
    Evans TG; Bussey L; Eagling-Vose E; Rutkowski K; Ellis C; Argent C; Griffin P; Kim J; Thackwray S; Shakib S; Doughty J; Gillies J; Wu J; Druce J; Pryor M; Gilbert S
    Lancet Infect Dis; 2022 Jun; 22(6):857-866. PubMed ID: 35305317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial.
    Widagdo W; Bastian AR; Jastorff AM; Scheys I; De Paepe E; Comeaux CA; Ligtenberg N; Callendret B; Heijnen E
    J Infect Dis; 2024 Aug; 230(2):e374-e383. PubMed ID: 38134393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
    Bernstein DI; Guptill J; Naficy A; Nachbagauer R; Berlanda-Scorza F; Feser J; Wilson PC; Solórzano A; Van der Wielen M; Walter EB; Albrecht RA; Buschle KN; Chen YQ; Claeys C; Dickey M; Dugan HL; Ermler ME; Freeman D; Gao M; Gast C; Guthmiller JJ; Hai R; Henry C; Lan LY; McNeal M; Palm AE; Shaw DG; Stamper CT; Sun W; Sutton V; Tepora ME; Wahid R; Wenzel H; Wohlbold TJ; Innis BL; García-Sastre A; Palese P; Krammer F
    Lancet Infect Dis; 2020 Jan; 20(1):80-91. PubMed ID: 31630990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.